Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 May-Jun;17(3):439-40.
doi: 10.4103/1008-682X.145069.

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer

Oliver Sartor  1 , Yan Dong  2
Affiliations
Comment

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer

Oliver Sartor et al. Asian J Androl. 2015 May-Jun.

Abstract

The recent manuscript in New England Journal of Medicine by Antonarakis et al. [1] has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3-1.4 months in AR-V7-positive patients as compared to 5.3-6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of AR-FL and AR-V7 structure. (a) AR transcripts. The solid and hatched boxes denote exons and cryptic exons, respectively. AR-FL: full-length androgen receptor; AR-V7: androgen receptor splice variant-7. (b) AR proteins. NTD: N-terminal domain; DBD: DNA-binding domain; H: hinge region; LBD: ligand-binding domain; U: unique C-terminal sequence.
See this image and copyright information in PMC

Comment on

  • AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.

References

    1. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38. - PMC - PubMed
    1. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469–77. - PMC - PubMed
    1. Zhang H, Zhan Y, Liu X, Qi Y, Zhang G, et al. Splicing variants of androgen receptor in prostate cancer. Am J Clin Exp Urol. 2013;1:18–24. - PMC - PubMed
    1. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–13. - PMC - PubMed
    1. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16–22. - PMC - PubMed

MeSH terms